Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
International Prognostic Factors Study Group; Lorch A, Beyer J, Bascoul-Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. International Prognostic Factors Study Group, et al. J Clin Oncol. 2010 Nov 20;28(33):4906-11. doi: 10.1200/JCO.2009.26.8128. Epub 2010 Oct 18. J Clin Oncol. 2010. PMID: 20956623
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K, Lotz JP, Germà-Lluch JR, Powles T, Kollmannsberger C, Beyer J. Lorch A, et al. J Clin Oncol. 2011 Jun 1;29(16):2178-84. doi: 10.1200/JCO.2010.32.6678. Epub 2011 Mar 28. J Clin Oncol. 2011. PMID: 21444870
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N, Fraslon C, Conseiller E, Granci V, Leblanc B, Pau B, Martineau P, Ychou M. Del Rio M, et al. J Clin Oncol. 2007 Mar 1;25(7):773-80. doi: 10.1200/JCO.2006.07.4187. J Clin Oncol. 2007. PMID: 17327601 Free PMC article.
Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).
Lagrange JL, Bascoul-Mollevi C, Geoffrois L, Beckendorf V, Ferrero JM, Joly F, Allouache N, Bachaud JM, Chevreau C, Kramar A, Chauvet B; Study Group on Genito-Urinary Tumors. Lagrange JL, et al. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):172-8. doi: 10.1016/j.ijrobp.2009.10.038. Epub 2010 Apr 10. Int J Radiat Oncol Biol Phys. 2011. PMID: 20385453 Clinical Trial.
SAE: an R package for early stopping rules in clinical trials.
Bascoul-Mollevi C, Laplanche A, Le Deley MC, Kramar A. Bascoul-Mollevi C, et al. Comput Methods Programs Biomed. 2011 Nov;104(2):243-8. doi: 10.1016/j.cmpb.2011.05.005. Epub 2011 Jul 7. Comput Methods Programs Biomed. 2011. PMID: 21741110 Clinical Trial.
Two-part statistics with paired data.
Bascoul-Mollevi C, Gourgou-Bourgade S, Kramar A. Bascoul-Mollevi C, et al. Stat Med. 2005 May 15;24(9):1435-48. doi: 10.1002/sim.1979. Stat Med. 2005. PMID: 15565738
Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality.
Copois V, Bibeau F, Bascoul-Mollevi C, Salvetat N, Chalbos P, Bareil C, Candeil L, Fraslon C, Conseiller E, Granci V, Mazière P, Kramar A, Ychou M, Pau B, Martineau P, Molina F, Del Rio M. Copois V, et al. J Biotechnol. 2007 Jan 20;127(4):549-59. doi: 10.1016/j.jbiotec.2006.07.032. Epub 2006 Aug 2. J Biotechnol. 2007. PMID: 16945445
50 results